M1069 is a selective and orall active, dual A_2A/A_2Badenosine receptor antagonistwith a selectivity of >100 fold against the A₁and A₃receptors. M1069 counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity^[1][2][3].

Metabolically stressful conditions, including inflammation and cancer, induces extracellular concentrations of adenosine increase^[1].
M1069 dose-dependently suppresses 5’-N-ethylcarboxamide adenosine (stable analog of adenosine)-stimulated cyclic adenosine monophosphate (cAMP) and phosphorylated cAMP- response element binding protein (pCREB) induction, inhibits interleukin (IL)-2 production^[1].
M1069 suppresses vascular endothelial growth factor (VEGF) production from human macrophages in adenosine-rich settings^[1].
M1069 inhibits protumorigenic cytokine secretion, such as CXCL1, CXCL5 and granulocyte-colony stimulating factor, and reduces IL-12 secretion from adenosine-differentiated dendritic cells^[1].
M1069 enhances T-cells activation in adenosine-differentiated dendritic cells^[1].

M1069 inhibits breast tumor (CD73hi/adenosine-rich 4T1 syngeneic) growth in vivo in mice and enhances chemotherapeutic agents efficacy^[1].

546.59

C₂₅H₃₀N₄O₈S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.